MS
CCCC icon

Mizuho Securities’s C4 Therapeutics CCCC Stock Holding History

Mizuho Securities’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-169,392
Closed -$6.41M – 199
2021
Q2 		$6.41M Hold
169,392
– – 1.23% 2
2021
Q1 		$6.27M Hold
169,392
– – 1.3% 2
2020
Q4 		$5.61M Buy
+169,392
New +$4.91M 1.1% 2

Other funds holding CCCC

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Mizuho Securities's CCCC Position: Q3 2021 in Review

Mizuho Securities sold out of C4 Therapeutics (CCCC) in Q3 2021, closing a stake of 169,392 shares — an estimated $6.41M sold.

Mizuho Securities first reported a position in CCCC in Q4 2020 and held it in 3 quarters. The position peaked at $6.41M in Q2 2021. 113 funds tracked by Wall St. Rank hold CCCC as of Q3 2021.

  • Mizuho Securities reported no remaining C4 Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Mizuho Securities sold 169,392 C4 Therapeutics shares in Q3 2021, an estimated $6.41M.
  • Mizuho Securities first reported a position in C4 Therapeutics in Q4 2020 and held it in 3 quarters.
  • Mizuho Securities's C4 Therapeutics position peaked at $6.41M in Q2 2021.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2021.

Based on Mizuho Securities's 13F filing for Q3 2021, filed 5 Nov 2021.